Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

4.63
-0.1100-2.32%
Post-market: 4.630.00000.00%19:30 EDT
Volume:2.99M
Turnover:14.05M
Market Cap:1.51B
PE:-11.22
High:4.86
Open:4.80
Low:4.63
Close:4.74
52wk High:7.30
52wk Low:3.69
Shares:325.83M
Float Shares:233.00M
Volume Ratio:0.59
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:3.90
PE(LYR):-13.58

Loading ...

Taysha Gene Therapies Q1 net loss widens on higher R&D costs

Reuters
·
May 06

Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate

Benzinga Earnings
·
May 06

BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million

Reuters
·
May 06

Taysha Gene Therapies Q1 Operating Income USD -43.486 Million

THOMSON REUTERS
·
May 06

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 06

Taysha Gene Therapies grants 188,000 RSUs to five new employees under inducement plan

Reuters
·
May 02

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 02

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

GlobeNewswire
·
Apr 29

Taysha Gene Therapies to present new TSHA-102 preclinical data at ASGCT annual meeting

Reuters
·
Apr 28

Taysha Gene Therapies announces annual shareholder meeting

Reuters
·
Apr 22

Unusually active option classes on open April 16th

TIPRANKS
·
Apr 16

U.S. Small Caps Finish Mixed As Taysha Gene Therapies Leads, BRP Lags

Dow Jones
·
Apr 16

Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside

TIPRANKS
·
Apr 15

Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000

Reuters
·
Apr 14

Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 06

Taysha Gene Therapies price target raised to $17 from $14 at Canaccord

TIPRANKS
·
Apr 06